Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background No consensus exists on how to reduce oral corticosteroids after the initiation of biologics in severe asthma. The PONENTE trial evaluated the effectiveness and safety of a rapid, individualised steroid-reduction algorithm, including adrenal insufficiency monitoring, after benralizumab initiation.Methods This multicentre, open-label, single-arm study was done at 138 clinical asthma treatment centres across 17 countries. We enrolled adult patients (age ≥18 years) with severe, eosinophilic asthma (blood eosinophil count ≥150 cells per μL at enrolment or ≥300 cells per μL in the previous year) requiring maintenance oral corticosteroids for at least 3 months preceding enrolment. Patients received benralizumab 30 mg (subcutaneous injection) every 4 weeks for three doses, then every 8 weeks thereafter. The oral corticosteroid reduction phase began at week 4 with daily oral corticosteroid dosages reduced by 1-5 mg every 1-4 weeks depending on the starting dosage, asthma control, and adrenal function status. Adrenal function was assessed with an early morning serum cortisol measurement, followed by adrenocorticotropic hormone stimulation when required, once patients achieved a daily oral corticosteroid dosage of 5 mg/day for 4 weeks. Repeat cortisol measurements were taken for patients with evidence of adrenal insufficiency at first testing. Asthma control was assessed with the Asthma Control Questionnaire-6 (ACQ-6) weekly throughout the induction and oral corticosteroid reduction phases. The primary endpoints were the percentage of patients eliminating daily oral corticosteroids, sustained for at least 4 weeks, and the percentage achieving elimination or a daily prednisone or prednisolone dosage of 5 mg or less, for at least 4 weeks, if the reason for no further reduction was adrenal insufficiency. Safety and efficacy analyses included all patients who received at least one dose of benralizumab and were descriptive. We present results after the oral corticosteroid reduction phase; a maintenance phase is ongoing. The trial is registered with ClinicalTrials.gov, NCT03557307.Findings Between April 1, 2018, and Sept 5, 2020, of 705 patients assessed for eligibility, 598 were recruited and all received at least one dose of benralizumab. Overall, 376 (62·88%, 95% CI 58·86-66·76) of 598 patients eliminated oral corticosteroids and 490 (81·94%, 78·62-84·94) of 598 eliminated use or achieved a dosage of 5 mg or less if the reason for stopping the reduction was adrenal insufficiency. Subgroup analysis showed that dosage reductions were achieved irrespective of baseline eosinophil count, baseline oral corticosteroid dosage, or oral corticosteroid treatment duration. Adrenal insufficiency was detected in 321 (60%) of 533 patients at first assessment and in 205 (38%) of 533 patients 2-3 months later. The safety profile was consistent with previous experience. Most patients (448 [75%] of 598) had no asthma exacerbations during the oral corticosteroid reduction phase with an annualised exacerbation rate of 0·63. Of 598 patients, 38 (6%) experienced a total of 46 exacerbations resulting in emergency department or urgent care visits or hospitalisations.Interpretation Despite a high prevalence of adrenal insufficiency, most patients with eosinophilic asthma treated with benralizumab achieved elimination of oral corticosteroids or maximal possible reduction using a personalised dosage-reduction algorithm.Funding AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the study by Menzies-Gow et al, 10% of patients showed recovered adrenal function after 3 months (42).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After long-term use of glucocorticoids, more rapid tapering of glucocorticoids when on a supraphysiologic dosing, followed by a slower taper when on physiologic glucocorticoid dosing, appears to be a safe strategy (42, 52).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The study by Menzies-Gow reported no adrenal crises, or (serious) adverse events related to adrenal insufficiency.”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationThe role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress
Smith, S. M., & Vale, W. W. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.4/ssmith · Cited by 1,948
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Self-citationEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationOral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Nair, P., Wenzel, S., Rabe, K. F., Bourdin, A., Lugogo, N. L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., & Goldman, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703501 · Cited by 1,044
Self-citationPrice, D. B., Trudo, F., Voorham, J., Xu, X., Kerkhof, M., Ling Zhi Jie, J., & Tran, T. N. (2018) · Journal of Asthma and Allergy · doi:10.2147/jaa.s176026 · Cited by 492
Self-citationAdrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
An expert consensus framework for asthma remission as a treatment goal
Menzies-Gow, A., Bafadhel, M., Busse, W. W., Casale, T. B., Kocks, J. W. H., Pavord, I. D., Szefler, S. J., Woodruff, P. G., de Giorgio-Miller, A., Trudo, F., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.12.006 · Cited by 434
Self-citationSystematic Literature Review of Systemic Corticosteroid Use for Asthma Management
Bleecker, E. R., Menzies-Gow, A. N., Price, D. B., Bourdin, A., Sweet, S., Martin, A. L., Alacqua, M., & Tran, T. N. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201904-0903so · Cited by 380
Self-citation
Cited by
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Wechsler, M. E., Nair, P., Terrier, B., Walz, B., Bourdin, A., Jayne, D. R. W., Jackson, D. J., Roufosse, F., Börjesson Sjö, L., Fan, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311155 · Cited by 228
Self-citationBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Jackson, D. J., Heaney, L. G., Humbert, M. J. C., Kent, B. D., Shavit, A., Hiljemark, L., Olinger, L., Cohen, D., Menzies-Gow, A. N., Korn, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02284-5 · Cited by 158
“9,15 However, there has also been concern regarding prolonged use of high-dose ICS, with some evidence showing dose-related increased risks of adverse events, including adrenal suppression, cataracts, osteoporosis-related fractures, and diabetes.”
Self-citationRhinovirus Infections and Their Roles in Asthma: Etiology and Exacerbations
Jackson, D. J., & Gern, J. E. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.01.006 · Cited by 198
Self-citationMenzies-Gow, A. N., Hoyte, F. C. L., Price, D. B., Cohen, D., Barker, P. N., Kreindler, J. L., Jison, M. L., Brooks, C. L., Papeleu, P., & Katial, R. K. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02098-1 · Cited by 165
“Moreover, results from the recent open-label PONENTE trial also underscore the advantages of precision treatments, as 63% of patients treated with benralizumab successfully eliminated OCS use while 82% eliminated OCS or achieved the maximum possible OCS reduction over the course of the study [44].”
ResultSelf-citation
Metadata
- Authors
- Menzies-Gow, A., Gurnell, M., Heaney, L. G., Corren, J., Bel, E. H., Maspero, J., Harrison, T., Jackson, D. J., Price, D., Lugogo, N., Kreindler, J., Burden, A., de Giorgio-Miller, A., Padilla, K., Martin, U. J., & Garcia Gil, E.
- Affiliations
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- University of Cambridge (GB)
- Queen's University Belfast (GB)
- University of California, Los Angeles (US)
- Amsterdam University Medical Centers (NL)
- AstraZeneca (United Kingdom) (GB)
- Guy's Hospital (GB)
- University of Aberdeen (GB)
- University of Michigan (US)
- AstraZeneca (United States) (US)
- Corresponding author
- Menzies-Gow, Andrew
- ORCID
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 10
- Issue
- 1
- Pages
- 47-58
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W3204022974
- Cited by
- 177
- References
- 31
- Citations by year
- 2026: 19 · 2025: 47 · 2024: 36 · 2023: 38 · 2022: 32
- FWCI
- 17.52
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-12-01)
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Respiratory Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Research Portal (King's College London) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, cc-by-nc-nd)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Keywords
- severe eosinophilic asthma, oral corticosteroid reduction, benralizumab, adrenal insufficiency, asthma control, serum cortisol, ACTH stimulation test, eosinophil count, treatment efficacy and safety, adult asthma
- MeSH terms
- Adolescent, Adrenal Cortex Hormones, Adult, Algorithms, Asthma, Double-Blind Method, Humans, Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. https://app.cochat.ai/papers/10.1016/s2213-2600(21)00352-0
- The paper
- Menzies-Gow, A., Gurnell, M., Heaney, L. G., Corren, J., Bel, E. H., Maspero, J., Harrison, T., Jackson, D. J., Price, D., Lugogo, N., Kreindler, J., Burden, A., de Giorgio-Miller, A., Padilla, K., Martin, U. J., & Garcia Gil, E. (2022). Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(21)00352-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.